

Zhejiang Medicine Co., Ltd.'s Overview

Overall Performance

Zhejiang Medicine's Profile

Headquarter

Parent Company

China

India

Zhejiang Medicine Co., Ltd.

Supplies for LSFF

Type of Ownership

Data unknown

Public

Supplies in India/Kenya?

Millers for Nutrition Partner

No

Supplies in other markets?

Data unknown

Micronutrient/premix applications

Data unknown


Fortificant Production Site Locations (Nr. of GPF-certified sites out of total sites) ²

China (Unknown)

Footnotes:

- 1. Large-scale food fortification
- 2. The company has at least 1 GPF-certified site globally


Overall Performance




Company engagement: Did not Engage

Important - The findings of this Assessment regarding companies' performance and their profile rely to a large extent on information shared by companies, in addition to information that is available in the public domain. Several factors beyond the companies' control may impact the availability of information. Therefore, in the case of limited or no engagement by such companies, this Assessment may not represent the full scope of their efforts or their profiles.

Company's performance across 4 thematic categories









- Relevant information found was fully disclosed
- Relevant information found partially disclosed (i.e. some information is confidential)
- O Relevant information was fully confidential



Commercial Nutrition Strategy Analysis

Findings
□ Commitments to address nutrition
No relevant information was found in the public domain or shared by the company; therefore it is not clear whether Zhejiang Medicine has commitments to address nutrition through its commercial operations (beyond supplying fortificants) and related governance systems in place.
☐ Responsible sales of fortificants
No information was found in the public domain, nor shared by Zhejiang Medicine, indicating whether the company prioritizes fortificant sales for products considered healthier by national or international public health authorities—relative to total fortificant sales in market-driven food fortification.
□ Nutrition-related business risks
No relevant information was found in the public domain nor shared by the company; therefore, it is unclear whether Zhejiang Medicine recognizes nutrition as a material business risk.



Commercial Nutrition Strategy Analysis

Recommendations
□ Commitments to address nutrition
Zhejiang Medicine is encouraged to assess all aspects of its business operations that could positively impact public health and nutrition, and to establish specific, measurable and time-bound commitments to act on these opportunities.
To strengthen transparency and accountability, the company should embed these commitments within a clear and cohesive nutrition strategy that aligns with its core business objectives and is publicly disclosed on its website.
By more formally integrating nutrition and fortification efforts into its corporate responsibility agenda, Zhejiang Medicine could better leverage both its commercial operations and broader initiatives to enhance its contribution to public health and nutrition. This approach would also position nutrition as a central component of the company's value proposition and long-term sustainability.
□ Reporting on nutrition progress
To strengthen accountability, transparency and recognition, Zhejiang Medicine is encouraged to regularly track and publicly report progress on its nutrition-related commitments and strategy against clear, well-defined metrics.
□ Nutrition governance
Zhejiang Medicine is encouraged to establish governance structures—such as board-level reviews—supported by clearly assigned responsibilities from executive staff and accountability mechanisms (e.g. linking progress to remuneration) to ensure effective delivery of its nutrition-related targets.
☐ Responsible sales of fortificants
To support healthier diets, Zhejiang Medicine is encouraged to prioritize fortificant sales for use in healthier products that align with national and international public health guidance—particularly in market-driven fortification beyond government-mandated staple food fortification. This includes stimulating fortification in products that contribute positively to nutritional outcomes and refraining from promoting the fortification of less healthy products that are high in sugar, salt, or unhealthy fats. By aligning its sales strategy and customer engagement with public health goals, the company can help ensure that fortification efforts contribute meaningfully to improved nutrition and long-term health
outcomes.
□ Nutrition-related business risks
Zhejiang Medicine is encouraged to explicitly assess and disclose whether nutrition constitutes a material risk within its overall risk portfolio. This should include evaluating potential impacts on business operations, reputation, regulatory compliance, and long-term sustainability.
Publicly reporting on such risks would align with corporate governance best practices, demonstrate a proactive approach to public health, and strengthen accountability to shareholders and stakeholders.



Engagement with Customers and Distributors Analysis

Findings Technical support to customers No relevant information was found in the public domain, nor shared by Zhejiang Medicine; therefore, it is unclear whether the company provides technical assistance to its customers to support the proper use of fortificants and effective fortification practices. Instructions on proper handling and use of fortificants

No relevant information was found in the public domain, nor shared by the company; therefore, it is

unclear whether Zhejiang Medicine provides instructions to its customers and distributors to

support the proper handling and use of fortificants across the value chain.

□ Technical support to customers

Zhejiang Medicine is encouraged to provide systematic technical support to its customers globally to strengthen fortification practices. To ensure consistency and effectiveness, the company should develop a structured technical assistance plan with measurable targets or key performance indicators. This plan could include training, research and development support, and other forms of guidance to address diverse customer needs.

Recommendations

In line with the Pan American Health Organization (PAHO) Code of Practice for Food Premix Operations, the company is also encouraged to collect detailed information on both the fortificant and the intended end-product. This should include micronutrient specifications, processing conditions, packaging, labelling, and shelf life. Gathering such data helps ensure that fortificants are appropriately formulated to meet specific customer needs, as well as national fortification regulations and dietary requirements.

The company is encouraged to publicly disclose on its website the support it provides for effective fortification, along with related outcomes, to strengthen transparency, accountability, and recognition.

☐ Instructions on proper handling and use of fortificants

Zhejiang Medicine is encouraged to provide clear, consistent, and comprehensive instructions to both customers and distributors on the appropriate handling and storage of fortificants. These guidelines should be aligned with recognized guidance—such as the PAHO Code of Practice for Food Premix Operations—to promote correct use and ensure effective fortification practices. The company is also encouraged to report publicly on these efforts.

In addition, the company should explicitly reference fortificant handling and storage requirements in formal distributor agreements. This would help prevent product mishandling and ensure accountability for maintaining fortificant quality.



Nutrition-Sensitive Activities Analysis

Findings Recommendations Nutrition-sensitive activities ■ Nutrition-sensitive activities No relevant information was found in the public domain, nor shared by the company; therefore, it is Zhejiang Medicine is encouraged to actively engage in partnerships with governments, unclear whether and how Zhejiang Medicine contributes to broader fortification efforts, beyond its development partners, and industry peers to support and advance global fortification core business operations (i.e. not directly targeted at customers). efforts and scale impact. To ensure these efforts are both impactful and aligned with public health priorities, the company is advised to develop structured implementation plans with clear, measurable targets that also reflect its strategic objectives. Transparency and accountability can be strengthened by publicly disclosing details of these partnerships—through annual reports or the company website—including implementation plans, progress metrics and outcomes. This would demonstrate commitment while highlighting the shared value and collective impact achieved.



Workforce Nutrition Analysis

Findings Recommendations Workforce nutrition programme **☐** Workforce nutrition programme No relevant information was found in the public domain, nor shared by the company; therefore, it is Zhejiang Medicine is encouraged to support employee health by developing a workforce unclear whether Zhejiang Medicine offers workplace nutrition programmes for employees—such as nutrition program that addresses healthy food at work, nutrition education, and improving access to healthy and safe foods at work, providing nutrition education, offering nutrition-focused health checks, with clear goals and objectives. Each pillar should nutrition-focused health checks, or supporting breastfeeding. include multiple elements. Practical guidance is available in the Workforce Nutrition Alliance guidebook series. Such a programme should ideally be accessible to all Paid maternity and secondary caregiver leave employees, including those at manufacturing sites. No relevant information was found in the public domain, nor shared by the company; therefore it is Breastfeeding support in the workplace unclear whether Zhejiang Medicine offers paid maternity or secondary caregiver leave to all Zhejiang Medicine should develop a comprehensive, company-wide policy to support employees. breastfeeding mothers and promote maternal and child health across all markets and worksites. This policy should include provisions for private, comfortable spaces for milk expression during paid breaks, refrigeration for safe storage, access to breastfeeding support services, and flexible work arrangements such as adjustable hours or on-site childcare. In addition, fostering a supportive workplace culture through breastfeeding awareness initiatives is recommended. □ Paid maternity and secondary caregiver leave Zhejiang Medicine is encouraged to develop a comprehensive policy that provides at least 18 weeks of paid maternity or primary caregiver leave, in line with International Labour Organization (ILO) recommendation, and ideally 26 weeks, as recommended by the World Health Organization (WHO), consistently for all employees including those at manufacturing sites, even where this goes beyond national regulatory requirements. The company is also encouraged to offer paid secondary caregiver leave that exceeds current national regulations.